Stock Events

Stock Events

Alkermes 

$49.50
47
+$0.02+0.04% 08:17 Today

Statistics

Day High
49.51
Day Low
49.48
52W High
55.67
52W Low
25.17
Volume
47,417
Avg. Volume
-
Mkt Cap
8.3B
P/E Ratio
57.71
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.55
-0.01
0.52
1.05
Expected EPS
-0.03513
Actual EPS
N/A

Financials

16.37%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.48BRevenue
241.66MNet Income

Analyst Ratings

56.17Average Price Target
The highest estimate is 65.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALKS. It's not an investment recommendation.
Amazon
15
AMZN
Tesla
13
TSLA
NVIDIA
13
NVDA
Apple
12
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, competes in the pharmaceuticals market, including CNS and mental health treatments, similar to Alkermes' focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company competes directly with Alkermes in the psychiatric and neurological drug markets, including treatments for depression and schizophrenia.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. offers products in various therapeutic areas that overlap with Alkermes, including treatments for mental health conditions.
Novartis
NVS
Mkt Cap286.78B
Novartis AG competes in the neuroscience segment, offering medications for neurological conditions, directly competing with Alkermes' portfolio.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. has a range of pharmaceutical products that compete with Alkermes, especially in the areas of health and well-being, including treatments for conditions affecting the central nervous system.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company has a diverse biopharmaceutical portfolio that includes psychiatric and neurological medications, competing with Alkermes.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.85B
Teva Pharmaceutical Industries Limited manufactures generic and specialty medicines, including CNS and neurology products, competing with Alkermes.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie Inc. competes with Alkermes in the neuroscience area, including R&D and marketing of psychiatric and neurological drugs.
Biogen
BIIB
Mkt Cap31B
Biogen Inc. focuses on neurology and has a strong presence in the neuroscience field, making it a direct competitor to Alkermes in areas like multiple sclerosis and psychiatric disorders.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. competes in the biopharmaceutical field, focusing on innovative treatments that could overlap with Alkermes' work in CNS disorders.

About

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Show more...
CEO
Blair Jackson
Employees
2050
Country
Ireland
ISIN
IE00B56GVS15
WKN
000A1JKVH

Listings

XETRA
DE
8AK.XETRA
MU
DE
8AK.MU
STU
DE
8AK.STU
F
DE
8AK.F

0 Comments

Share your thoughts

FAQ

What is Alkermes stock price today?▼
The current price of ALKS is $49.50 USD — it has increased by +0.04% in the past 24 hours. Watch Alkermes stock price performance more closely on the chart.
What is Alkermes stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Alkermes stocks are traded under the ticker ALKS.
Is Alkermes stock price growing?▼
ALKS stock has fallen by -1.59% compared to the previous week, the month change is a -6.15% fall, over the last year Alkermes has showed a +71.51% increase.
What is Alkermes market cap?▼
Today Alkermes has the market capitalization of 8.3B
When is the next Alkermes earnings date?▼
Alkermes is going to release the next earnings report on October 28, 2026.
What were Alkermes earnings last quarter?▼
ALKS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.03 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alkermes revenue for the last year?▼
Alkermes revenue for the last year amounts to 1.48B USD.
What is Alkermes net income for the last year?▼
ALKS net income for the last year is 241.66M USD.
How many employees does Alkermes have?▼
As of August 19, 2026, the company has 2,050 employees.
In which sector is Alkermes located?▼
Alkermes operates in the Health & Wellness sector.
When did Alkermes complete a stock split?▼
The last stock split for Alkermes was on May 15, 2000 with a ratio of 2:1.
Where is Alkermes headquartered?▼
Alkermes is headquartered in DUBLIN 4, Ireland.